Compass Therapeutics, Inc. (CMPX)
Nasdaq · Healthcare · Biotechnology
$0.9606+12.13%as of Oct 6, 2026, 4:35 AM ET
- Market cap
- $173M
- 52-week range
- $0.829 – $6.88
- 52-week change
- −76.65%
- EPS (trailing)
- −$0.39
- Analyst rating
- 1.5 Strong buy
- Next earnings
- Nov 5, 2026
Fiscal year to Dec 2025
- Revenue
- $0K (−100.00%)
- Net income
- −$66.5M
- Free cash flow
- −$49.2M
From the company’s annual report on SEC EDGAR.
About Compass Therapeutics, Inc.
Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, develops antibody-based therapeutics for the treatment of various human diseases in the United States. The company's lead product candidate, tovecimig, is a bispecific antibody that targets delta-like ligand 4 (DLL4) and vascular endothelial growth factor A (VEGF-A), which are critical to angiogenesis and tumor vascularization. It also develops CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells; CTX-8371, a bispecific inhibitor that targets programmed cell death protein-1 (PD-1) and ligand PD-L1 checkpoint inhibitor antibodies; and CTX-10726, a bispecific antibody that targets PD-1 and VEFG-A. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Headquarters: Boston, United States · 39 employees · compasstherapeutics.com